Clinical Cancer Research, Vol 3, Issue 11 1959-1968, Copyright © 1997 by American Association for Cancer Research

ARTICLES

A phase I trial of retroviral BRCA1sv gene therapy in ovarian cancer

DL Tait, PS Obermiller, S Redlin-Frazier, RA Jensen, P Welcsh, J Dann, MC King, DH Johnson and JT Holt
Vanderbilt University Medical Center, Departments of Obstetrics and Gynecology, Cell Biology, Pathology, and Medicine, Nashville, Tennessee 37232-6838, USA.

Gene transfer of BRCA1sv (a normal splice variant of BRCA1) into ovarian cancer cells produces growth inhibition in vitro and tumor suppression in nude mouse xenografts. As an initial step toward gene replacement therapy for ovarian cancer, we conducted a Phase I trial to assess the pharmacokinetics and toxicity of i.p. BRCA1sv retroviral vector therapy. Following placement of an indwelling Port-a-Cath in patients, a dose escalation study was performed of four daily i.p. infusions spanning doses from 3 to 300 ml (i.e., 10(10) viral particles) at half-log intervals (23 cycles in 12 patients). Gene transfer and expression were documented by PCR, Southern blot, reverse transcription-PCR, and nuclease protection assays. Pharmacokinetics were assessed by PCR and Southern blots detecting vector DNA, and toxicity was evaluated by clinical exam and fluid analysis. Three of 12 patients developed an acute sterile peritonitis, which spontaneously resolved within 48 h. Plasma and peritoneal antibodies to the retroviral envelope protein were detected only in patients treated with the highest dose levels but not in others, despite repeat dosing for an interval of up to 4 months. Eight patients showed stable disease for 4-16 weeks, and three patients showed tumor reduction with diminished miliary tumor implants at reoperation (two patients) and radiographic shrinkage of measurable disease (one patient). The vector-related complication of peritonitis was observed in three patients but resolved quickly as in preclinical mouse studies. Ovarian cancer may provide an important model for retroviral gene therapy studies due to vector stability, minimal antibody response, and access to tumor by i.p. therapy.

This article has been cited by other articles:

				J. I. Weberpals, K. V. Clark-Knowles, and B. C. Vanderhyden Sporadic Epithelial Ovarian Cancer: Clinical Relevance of BRCA1 Inhibition in the DNA Damage and Repair Pathway J. Clin. Oncol., July 1, 2008; 26(19): 3259 - 3267. [Abstract] [Full Text] [PDF]

				L. Barzon, M. Boscaro, and G. Palu Endocrine Aspects of Cancer Gene Therapy Endocr. Rev., February 1, 2004; 25(1): 1 - 44. [Abstract] [Full Text] [PDF]

				M. Navo and J. A. Smith Update on the Prevention and Treatment of Ovarian Cancer Journal of Pharmacy Practice, June 1, 2003; 16(3): 149 - 156. [Abstract] [PDF]

				J. P. Geisler, M. A. Hatterman-Zogg, J. A. Rathe, and R. E. Buller Frequency of BRCA1 Dysfunction in Ovarian Cancer J Natl Cancer Inst, January 2, 2002; 94(1): 61 - 67. [Abstract] [Full Text] [PDF]

				R. D. Alvarez, M. N. Barnes, J. Gomez-Navarro, M. Wang, T. V. Strong, W. Arafat, R. B. Arani, M. R. Johnson, B. L. Roberts, G. P. Siegal, et al. A Cancer Gene Therapy Approach Utilizing an Anti-erbB-2 Single-Chain Antibody-encoding Adenovirus (AD21): A Phase I Trial Clin. Cancer Res., August 1, 2000; 6(8): 3081 - 3087. [Abstract] [Full Text]

				D. L. Tait, P. S. Obermiller, A. R. Hatmaker, S. Redlin-Frazier, and J. T. Holt Ovarian Cancer BRCA1 Gene Therapy: Phase I and II Trial Differences in Immune Response and Vector Stability Clin. Cancer Res., July 1, 1999; 5(7): 1708 - 1714. [Abstract] [Full Text] [PDF]

				J. A Smith and B. R Goldspiel Cancer gene therapy update Journal of Oncology Pharmacy Practice, March 1, 1999; 5(1): 7 - 21. [Abstract] [PDF]

				T. Ouchi, S. W. Lee, M. Ouchi, S. A. Aaronson, and C. M. Horvath Collaboration of signal transducer and activator of transcription 1 (STAT1) and BRCA1 in differential regulation of IFN-gamma target genes PNAS, May 9, 2000; 97(10): 5208 - 5213. [Abstract] [Full Text] [PDF]